McLean, Anna
Maple-Brown, Louise
Murphy, Helen R.
Funding for this research was provided by:
NIHR EME (16/35/01)
Juvenile Diabetes Research Foundation International (2-RSC-2019-828-M-N, 22-2013-266)
NHS England and the Welsh government (National Pregnancy in Diabetes audit (NPID))
National Health and Medical Research Council (#1168623, #1194698)
Queensland Health New Technology and Evaluation Fund (QCOS32950)
Article History
Received: 5 March 2024
Accepted: 20 May 2024
First Online: 5 July 2024
Acknowledgements
: The Diabetes across the Lifecourse: Northern Australian Partnership would not be possible without invaluable contributions from members of the Aboriginal and Torres Strait Islander Advisory Group, Steering Committee, Management Group, and partners including government, non-government and Aboriginal community-controlled health organisations.
: LM-B’s work was supported by an NHMRC Investigator grant (#1194698) and AM’s work was supported by an NHMRC postgraduate scholarship (#1168623) and Queensland Health New Technology and Evaluation Fund (QCOS32950). The National Pregnancy in Diabetes (NPID) audit is commissioned by the Healthcare Quality Improvement Partnership (HQIP) as part of the National Clinical Audit (NCA) programme funded by NHS England and the Welsh government. The audit is prepared in collaboration with NHS Digital and supported by Diabetes UK and Public Health England. HRM’s work on CamAPS FX hybrid closed-loop (AiDAPT) was funded by the Efficacy and Mechanism Evaluation (EME) Programme, an MRC and NIHR partnership, with trial data management and statistical centre support from JDRF awards #22-2013-266 and #2-RSC-2019-828-M-N. The views expressed in this publication are those of the authors and not necessarily those of the MRC, NIHR or the Department of Health and Social Care.
: HRM serves on the Medtronic European and the Ypsomed Scientific Advisory Boards, reports research devices at reduced and no cost from Abbott Diabetes Care (no cost), Dexcom (reduced cost) and Medtronic (no cost), speaker honoraria from Abbott Diabetes Care, Dexcom, Eli Lilly, Medtronic, Novo Nordisk, Sanofi and Ypsomed. She chairs the National Pregnancy in Diabetes (NPID) audit and is a member of the editorial boards for Diabetes Care and Diabetologia journals. AM and LM-B declare that there are no relationships or activities that might bias, or be perceived to bias, their work.
: All authors were responsible for drafting the article and reviewing it critically for important intellectual content. All authors approved the version to be published.